Immune Checkpoint Inhibitors (ICI) in Advanced and Recurrent Endometrial Cancer

2022 ◽  
Vol 20 (1) ◽  
Author(s):  
Chinmoy K. Bose
Keyword(s):  
Endometrial Cancer ◽  
Immune Checkpoint ◽  
Immune Checkpoint Inhibitors ◽  
Checkpoint Inhibitors ◽  
Recurrent Endometrial Cancer

scholarly journals Role of Immune Checkpoint Inhibitors in Advanced or Recurrent Endometrial Cancer

Cureus ◽  
2018 ◽  
Author(s):  
Ena Arora ◽  
Muhammad Masab ◽  
Priyanka Mittar ◽  
Vishal Jindal ◽  
Sorab Gupta ◽  
...  
Keyword(s):  
Endometrial Cancer ◽  
Immune Checkpoint ◽  
Immune Checkpoint Inhibitors ◽  
Checkpoint Inhibitors ◽  
Recurrent Endometrial Cancer

Immune checkpoint inhibitors in endometrial cancer

2021 ◽  
pp. 103306
Author(s):  
C. Gómez-Raposo ◽  
M. Merino Salvador ◽  
C. Aguayo Zamora ◽  
B. García de Santiago ◽  
E. Casado Sáenz
Keyword(s):  
Endometrial Cancer ◽  
Immune Checkpoint ◽  
Immune Checkpoint Inhibitors ◽  
Checkpoint Inhibitors

scholarly journals Immune Checkpoint Inhibitors: A Promising Choice for Endometrial Cancer Patients?

2020 ◽  
Vol 9 (6) ◽  
pp. 1721 ◽  
Author(s):  
Lucia Musacchio ◽  
Serena Maria Boccia ◽  
Giuseppe Caruso ◽  
Giusi Santangelo ◽  
Margherita Fischetti ◽  
...  
Keyword(s):  
Endometrial Cancer ◽  
Immune Checkpoint ◽  
Immune Checkpoint Inhibitors ◽  
Immune Escape ◽  
Checkpoint Inhibitors ◽  
Tumor Immune Escape ◽  
Solid Malignancies ◽  
Programmed Death ◽  
Therapy Strategies

Although around 80% of endometrial cancers are diagnosed at early stages and present with a 5-year survival rate exceeding 95%, patients with advanced and recurrent disease show a poor prognosis and low response rates to standard chemotherapy. In the era of targeted therapy, the great advances in the understanding of programmed death-ligand 1 (PD-L1) upregulation in cancer cells, which is responsible for tumor immune escape, have contributed to the increasing interest in immune checkpoint inhibitors as a promising strategy for the treatment of several refractory solid malignancies, including endometrial cancer. Several clinical trials have investigated the efficacy and safety of immune checkpoint inhibitors in endometrial cancer, which already led to the approval of the anti-programmed cell death protein 1 (anti-PD-1) antibody pembrolizumab as a satisfactory alternative for selected patients with unresectable or metastatic disease. As the future of cancer treatment will probably rely on combination therapy strategies, currently, innovative ongoing trials are exploring the potential role of immune checkpoint inhibitors associated with chemotherapy, radiotherapy, and other targeted therapies. Moreover, further research is warranted to discover new specific biomarkers that can accurately predict the response to immunotherapy.

scholarly journals PD-1 Inhibitor Therapy in a Patient with Preexisting P-ANCA Vasculitis: A Case Report and Review of the Literature

2020 ◽  
Vol 2020 ◽  
pp. 1-5
Author(s):  
Amanda Ramos ◽  
Marcela del Carmen ◽  
Oladapo Yeku
Keyword(s):  
Endometrial Cancer ◽  
Autoimmune Diseases ◽  
Immune Checkpoint ◽  
Immune Checkpoint Inhibitors ◽  
Immune Checkpoint Inhibitor ◽  
Checkpoint Inhibitor ◽  
Checkpoint Inhibitors ◽  
Endometrial Adenocarcinoma ◽  
Anca Vasculitis ◽  
Definitive Therapy

Background. Recurrent endometrial cancer after definitive therapy is a lethal disease. Recently, immune checkpoint inhibitors (ICI) have improved the management of mismatch repair-deficient (MSI-H) endometrial cancer. Autoimmune side effects are known to occur with ICI. As a result, patients with preexisting autoimmune diseases are excluded from studies involving these drugs. This has led to challenges in clinical practice regarding the use of ICI in otherwise eligible patients with underlying autoimmune disease. Case Presentation. We present the case of an 81-year-old woman with an underlying autoimmune vasculitis and recurrent, metastatic endometrial adenocarcinoma with microsatellite instability, who was treated with an immune checkpoint inhibitor. This patient received pembrolizumab, an immune checkpoint inhibitor that targets the programmed cell death-1 immune checkpoint. Ultimately, she was treated for 4 months with pembrolizumab and benefited from stable disease during this period. She remained asymptomatic from her underlying autoimmune P-ANCA vasculitis. A review of the scientific literature reveals several cases of the successful use of immune checkpoint inhibitors in patients with autoimmune diseases, including systemic lupus erythematosus, rheumatoid arthritis, and inflammatory bowel disease. Conclusion. This is one of the first reports of a patient with an underlying autoimmune vasculitis successfully treated with an immune checkpoint inhibitor without exacerbating her underlying autoimmune condition. Carefully selected patients with underlying autoimmune vasculitis can be safely treated with ICI.

scholarly journals Microsatellite instability is a biomarker for immune checkpoint inhibitors in endometrial cancer

Oncotarget ◽  
2017 ◽  
Vol 9 (5) ◽  
pp. 5652-5664 ◽  
Author(s):  
Hitomi Yamashita ◽  
Kentaro Nakayama ◽  
Masako Ishikawa ◽  
Kohei Nakamura ◽  
Tomoka Ishibashi ◽  
...  
Keyword(s):  
Endometrial Cancer ◽  
Microsatellite Instability ◽  
Immune Checkpoint ◽  
Immune Checkpoint Inhibitors ◽  
Checkpoint Inhibitors

scholarly journals Pharmacological Treatment of Advanced, Persistent or Metastatic Endometrial Cancer: State of the Art and Perspectives of Clinical Research for the Special Issue “Diagnosis and Management of Endometrial Cancer”

Cancers ◽  
2021 ◽  
Vol 13 (24) ◽  
pp. 6155
Author(s):  
Angiolo Gadducci ◽  
Stefania Cosio
Keyword(s):  
Endometrial Cancer ◽  
Hormonal Therapy ◽  
Immune Checkpoint ◽  
Pharmacological Treatment ◽  
Immune Checkpoint Inhibitors ◽  
Checkpoint Inhibitors ◽  
Single Agent ◽  
Objective Response ◽  
First Line ◽  
Platinum Based Chemotherapy

Patients with metastatic or recurrent endometrial cancer (EC) not suitable for surgery and/or radiotherapy are candidates for pharmacological treatment frequently with unsatisfactory clinical outcomes. The purpose of this paper was to review the results obtained with chemotherapy, hormonal therapy, biological agents and immune checkpoint inhibitors in this clinical setting. The combination of carboplatin (CBDCA) + paclitaxel (PTX) is the standard first-line chemotherapy capable of achieving objective response rates (ORRs) of 43–62%, a median progression-free survival (PFS) of 5.3–15 months and a median overall survival (OS) of 13.2–37.0 months, respectively, whereas hormonal therapy is sometimes used in selected patients with slow-growing steroid receptor-positive EC. The combination of endocrine therapy with m-TOR inhibitors or cyclin-dependent kinase 4/6 inhibitors is currently under evaluation. Disappointing ORRs have been associated with epidermal growth factor receptor (EGFR) inhibitors, HER-2 inhibitors and multi-tyrosine kinase inhibitors used as single agents, and clinical trials evaluating the addition of bevacizumab to CBDCA + PTX have reported conflicting results. Immune checkpoint inhibitors, and especially pembrolizumab and dostarlimab, have achieved an objective response in 27–47% of highly pretreated patients with microsatellite instability-high (MSI-H)/mismatch repair (MMR)-deficient (-d) EC. In a recent study, the combination of lenvatinib + pembrolizumab produced a 24-week response rate of 38% in patients with highly pretreated EC, ranging from 64% in patients with MSI-H/MMR-d to 36% in those with microsatellite stable/MMR-proficient tumors. Four trials are currently investigating the addition of immune checkpoint inhibitors to PTX + CBDCA in primary advanced or recurrent EC, and two trials are comparing pembrolizumab + lenvatinib versus either CBDCA + PTX as a first-line treatment of advanced or recurrent EC or versus single-agent chemotherapy in advanced, recurrent or metastatic EC after one prior platinum-based chemotherapy.

Abstract #827: Panhypopituitarism Due to Immune Checkpoint Inhibitors

2017 ◽  
Vol 23 ◽  
pp. 176-177
Author(s):  
Kaitlyn Steffensmeier ◽  
Bahar Cheema ◽  
Ankur Gupta
Keyword(s):  
Immune Checkpoint ◽  
Immune Checkpoint Inhibitors ◽  
Checkpoint Inhibitors
Sign in / Sign up

Export Citation Format

Share Document